Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The only substantive FDA-label claim present (fetal toxicity in pregnancy, increased fetal/neonatal morbidity and death especially in 2nd/3rd trimesters, and discontinuation when pregnancy is detected) is directly supported by the provided AVAPRO (irbesartan) label excerpts, with no contradictions.
Category Scores
Accurate Statements
AVAPRO causes fetal harm when administered during pregnancy, with increased fetal/neonatal morbidity and death (notably during the 2nd and 3rd trimesters).
Supported by Label Sections 5.1 (Fetal Toxicity) and 8.1 (Pregnancy): “AVAPRO can cause fetal harm… during the second and third trimesters… increases fetal and neonatal morbidity and death.”
AVAPRO should be discontinued when pregnancy is detected as soon as possible.
Supported by Label Sections 5.1 (Fetal Toxicity) and 8.1 (Pregnancy): “When pregnancy is detected, discontinue AVAPRO as soon as possible.”
Unsupported Statements
Statements in the provided list (e.g., dosing strength, treatment of high blood pressure, kidney protection in type 2 diabetes, side effects) are not evaluated against label text because the prompt only provided pregnancy/fetal toxicity label excerpts.
No supporting FDA label excerpts for these claims were provided in the prompt; therefore support/contradiction cannot be assessed from the supplied materials.
Contradictions
Important Omissions
The response does not mention pregnancy counseling elements (e.g., advising childbearing-age women to report pregnancies) or the detailed fetal/neonatal adverse reaction list (e.g., anuria, renal failure, hypotension) because only a single claim about fetal harm/discontinuation was evaluated.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The key pregnancy safety warning included is accurately represented and aligns with label-required discontinuation guidance when pregnancy is detected.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Other non-pregnancy claims listed were not assessable against the provided label excerpts.
Suggested Improvement
Limit claims to label-provided excerpts or include the corresponding FDA label sections (e.g., Indications, Dosage and Administration, Adverse Reactions) for full alignment assessment.